Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid Makers May Have To Pay For Prevention Costs Of 'Man-Made Plague,' Judge Suggests

Executive Summary

Bellwether trial set to begin in September after judge says cities may be able to recover damages for cost of governmental services that are the result of defendants' alleged conduct.

You may also be interested in...



Behind-The-Scenes Battles As Opioid MDL Jury Trial Nears

Expert witness "battle plan," requests for summary judgment, and squabble over DEA drug distribution data offer preview of the first US bellwether trial against opioid manufacturers, distributors and pharmacies.

Opioid Exposure Risk Intensifying For Generic Drug Makers

Business fundamentals took a back seat to opioid litigation in the second quarter for generic drug makers, including Teva, Mallinckrodt and Endo Pharmaceuticals.

J&J Gambles Oklahoma Opioid Trial Is Better Than Settlement; State Seeks $870m Per Year

In opening statements, Oklahoma suggests award could be 'just shy of $13bn' if it takes 20 years to fix the problem.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS124655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel